National Cancer Institute
at the National Institutes of Health
Leukemia Trial Results
- Ibrutinib Improves Survival Compared with Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia
(Posted: 06/27/2014) - In an international randomized phase III clinical trial, patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were treated with ibrutinib (Imbruvica®) lived longer without their disease getting worse than patients who received ofatumumab (Arzerra®). Patients who received ibrutinib also lived longer and were more likely to show a clinical response to treatment than those who received ofatumumab.
- Combination of Idelalisib and Rituximab Improves Survival in Patients with Relapsed Chronic Lymphocytic Leukemia
(Posted: 03/12/2014) - In an international randomized double-blind phase III clinical trial, patients with relapsed chronic lymphocytic leukemia (CLL) who received the investigational drug idelalisib in combination with rituximab (Rituxan®) lived substantially longer without their disease getting worse than patients who received a placebo plus rituximab.
Overall survival was also improved in patients who received idelalisib plus rituximab. Patients who received idelalisib and rituximab were also more likely to live 12 months after beginning treatment and to have their cancer regress compared with patients who received a placebo plus rituximab.
- Combination of Obinutuzumab Plus Chlorambucil Improves Survival in Patients with Chronic Lymphocytic Leukemia and Other Health Conditions
(Posted: 02/21/2014) - In an international randomized phase III trial, previously untreated patients with chronic lymphocytic leukemia and other health conditions who received a combination of obinutuzumab (Gazyva™) and chlorambucil (Leukeran®) lived longer without their disease getting worse (progression-free survival) and had better overall survival than patients who received chlorambucil alone.
- New Drug Shows Promise against Drug-Resistant Leukemias
(Posted: 12/17/2012) - A new drug called ponatinib may be a new treatment option for patients with chronic myeloid leukemia (CML) that is resistant to other therapies, according to results of two early clinical trials.
- More Chemotherapy May Help after Initial Treatment for Childhood Leukemia Fails
(Posted: 06/07/2012) - A study suggests that at least some children diagnosed with acute lymphoblastic leukemia who respond poorly to initial chemotherapy may do better if they receive additional chemotherapy rather than a stem cell transplant.